Evolocumab Cuts Heart Attack Risk by 31%: PCSK9 Inhibitors May Reshape Prevention

What Does the New Evolocumab Research Show About Heart Attack Prevention?

Evolocumab (marketed as Repatha by Amgen) belongs to the PCSK9 inhibitor drug class — monoclonal antibodies that dramatically lower LDL cholesterol by blocking the PCSK9 protein, which normally degrades LDL receptors on liver cells. With PCSK9 blocked, more LDL receptors remain active on the liver surface, clearing more "bad" cholesterol from the bloodstream. Clinical data have consistently shown that evolocumab can reduce LDL-C levels by 50–60% when added to statin therapy.

The latest analysis suggests that evolocumab reduces the risk of myocardial infarction by approximately 31%. While the drug has primarily been used in patients who already have established atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia, these findings raise the question of whether PCSK9 inhibitors could play a larger role in primary prevention — particularly for high-risk patients whose LDL remains elevated despite maximum-tolerated statin therapy.

How Do PCSK9 Inhibitors Compare to Statins for Cholesterol Lowering?

Statins remain the cornerstone of cholesterol management and cardiovascular prevention, with decades of evidence supporting their efficacy and safety. High-intensity statins such as atorvastatin and rosuvastatin can reduce LDL cholesterol by 30–50%. However, a significant proportion of patients either cannot tolerate statins due to side effects such as myalgia, or fail to reach guideline-recommended LDL targets despite maximum doses. This is where PCSK9 inhibitors fill a critical therapeutic gap.

The landmark FOURIER trial, published in the New England Journal of Medicine in 2017, demonstrated that adding evolocumab to statin therapy significantly reduced the composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The trial enrolled over 27,000 patients with established ASCVD. The new findings build on this evidence base, with researchers reporting that the heart attack risk reduction may be even more pronounced in certain patient subgroups, highlighting the importance of personalized treatment approaches.

Who Should Consider PCSK9 Inhibitor Therapy in 2026?

According to guidelines from the American College of Cardiology (ACC) and the American Heart Association (AHA), PCSK9 inhibitors are recommended for patients with clinical ASCVD who require additional LDL lowering beyond maximally tolerated statin and ezetimibe therapy. They are also indicated for patients with heterozygous or homozygous familial hypercholesterolemia. Cost has historically been a barrier to wider adoption, though prices have dropped considerably since the drugs' initial launch in 2015.

The new research showing a 31% reduction in heart attack risk adds to growing momentum for broader use. Cardiovascular disease remains the leading cause of death globally, claiming an estimated 17.9 million lives annually according to the World Health Organization. If PCSK9 inhibitors can meaningfully reduce events in a wider population — particularly those at high cardiovascular risk who have not yet experienced a first event — the public health implications could be substantial. Clinicians are watching closely for updated guideline recommendations that may reflect this expanding evidence base.